Andrew Reardon, CLO & Secretary at LIGAND PHARMACEUTICALS INC (LGND), sold 5,000 shares at $308.99 ($1.6M) on 2026-07-01, disclosed to the SEC on 2026-07-06.
Scheduled sale ($1.6M) by CLO & Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $308.99 | 396 | $122K | 7.8% |
| 2 | $310.20 | 104 | $32K | 2.1% |
| 3 | $311.72 | 1,119 | $349K | 22.3% |
| 4 | $312.28 | 1,081 | $338K | 21.6% |
| 5 | $313.46 | 700 | $219K | 14.0% |
| 6 | $314.58 | 100 |
| $31K |
| 2.0% |
| 7 | $315.78 | 900 | $284K | 18.1% |
| 8 | $317.15 | 600 | $190K | 12.1% |
| Total | $313.28 avg | 5,000 | $1.6M | 100% |
| Filing → |
| LGND | SELL | 2026-08-04 | $1.4M | — | Filing → |
| LGND | SELL | 2026-06-02 | $1.1M | — | Filing → |
| LGND | SELL | 2026-05-04 | $1.2M | — | Filing → |